Tatyana Worthy

机构：National Institutes of Health, National Heart, Lung, and Blood Institute

发表论文 23 篇 · 总被引 924 次 · h-index 9

代表论文

• Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer (2014 · Journal of Clinical Oncology · 被引 715)
• 90 Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma (2015 · Proceedings of the National Academy of Sciences · 被引 49)
• A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo‐immunized patients (2020 · British Journal of Haematology · 被引 31)
• Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia (2018 · Blood · 被引 29)
• Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation (2017 · Bone Marrow Transplantation · 被引 23)
• Effects of Sirolimus on Anti-SARS-CoV-2 Vaccination in Patients With Lymphangioleiomyomatosis (2023 · CHEST Journal · 被引 17)